Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Langdon (NPI 1689654618)

Field	Value
Entity Type	Individual
Organization	Robert Langdon
Address	8303 Dodge St
City	Omaha
State	NE
ZIP	68114
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 17, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider is effectively single-payer: total Medicare revenue is $1.4M and there is no Medicaid billing on file, so Medicare represents the sole reported public-payer revenue stream for this NPI. The absence of Medicaid activity means analyses of payer mix and access to low-income populations must rely on Medicare-only patterns.

Revenue is highly concentrated in three injectable therapies: J9271, J1930, and J1569 together account for 72.8% of the provider's total Medicare revenue. In particular, J9271 (pembrolizumab) alone represents $481.7K or 34.9% of Medicare revenue, while J1930 (lanreotide) contributes $306.2K (22.2%) and J1569 (immune globulin) contributes $217.8K (15.8%).

The code mix indicates an infusion‑centric hematology/oncology practice that delivers high-cost biologics and supportive infusions in an outpatient or office setting. Top revenue drivers are oncology/immunotherapy and specialty injectables (J9271, J1930, J1569), supported by chemotherapy administration codes (96413, 96365, 96417) and office E/M codes (99214, 99213), consistent with integrated infusion plus outpatient management.

Competitive standing varies by drug: the provider's J9271 volume is typical nationally (rank #1027 of 1841, 44th percentile), indicating a modest presence for pembrolizumab relative to peers, while J1930 ranks #18 of 56 (67th percentile) and J1569 ranks #133 of 542 (75th percentile), showing stronger placement among lanreotide and immune globulin prescribers. These rank/percentile signals suggest the provider is a relatively important regional supplier for some specialty injectables but only a typical participant for the highest-revenue oncology immunotherapy nationally.

Office visit billing is an outlier: 99214 has 1.5K claims producing $127.4K and is labeled an "extreme outlier" (rank #3736 of 479517, 99th percentile). This unusually high E/M volume for 99214 indicates a heavy office-based management workload or complex follow-up care compared with national peers and is a dominant non-drug revenue contributor.

The practice reports very large claim counts for several low-paid HCPCS drug lines—J0881 shows 14K claims for $27.9K revenue (2.0%), and J1439 shows 12.8K claims for $12.8K revenue (0.9%). These patterns—many claims with low average payment—point to frequent administration or per-unit billing of lower-dollar products in addition to the high-cost biologics that drive overall revenue.

Ancillary and lab utilization is above typical for some common tests: 80053 (CMP) has 1.2K claims and ranks #1224 of 26416 (95th percentile), and 85025 (CBC) has 1.4K claims and ranks #1543 of 32833 (95th percentile). This suggests the provider orders routine labs at higher-than-typical rates for a single NPI, consistent with ongoing infusion monitoring and oncology patient management.

The provider has an established NPI (enumerated 2006-01-17, noted as ~20 years ago), which aligns with the combination of sustained Medicare revenue and an infusion-oriented code mix; tenure supports the interpretation of an ongoing outpatient oncology/hematology practice rather than a newly formed clinic.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,200	$40	$481.7K
J1930	Injection, lanreotide, 1 mg	6,960	$40	$306.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,050	$40	$217.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,480	$90	$127.4K
J0897	Injection, denosumab, 1 mg	3,420	$20	$61.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$90	$30.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	13,960	$1	$27.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	310	$60	$18.3K
J1439	Injection, ferric carboxymaltose, 1 mg	12,750	$1	$12.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	100	$130	$12.2K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Robert Langdon — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	19	30	14,400	$40	$671.6K
J1930	1	10	6,960	$40	$306.6K
J1569	4	10	5,980	$40	$224.3K
J0897	57	200	2,040	$20	$62.7K
J0881	9	10	17,260	$1	$54.5K
J1439	27	30	25,880	$1	$26.4K
96413	25	80	60	$90	$18.2K
99214	26	3,210	110	$70	$14.9K
J3490	11	30	60	$160	$11.3K
96401	21	30	120	$50	$11K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Langdon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Robert Langdon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Hospital & Medical Center	NE	Children's Hospital	$0	$89.8M
Children's Physicians	NE	Pediatrics Physician	$0	$39.4M
Nebraska Pediatric Practice, Inc	NE	Pediatrics Physician	$0	$29M
Physicians Clinic Inc	NE	Family Medicine Physician	$0	$20.5M
Nebraska Methodist Hospital	NE	General Acute Care Hospital	$0	$14.5M
Smiles 4 Kids PC	NE	General Practice Dentistry	$0	$11.5M
Children's Hospital	NE	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.4M
Nebraska Methodist Hospital	NE	Emergency Medicine Physician	$0	$5.3M
Unmc College Of Dentistry	NE	Dentist	$0	$4.8M
Stones Worth Stepping, P.C.	NE	Occupational Therapist	$0	$4.7M

Robert Langdon — Billing Profile & Reimbursement Data

Sign up for Robert Langdon — Billing Profile & Reimbursement Data policy alerts

Robert Langdon — Billing Profile & Reimbursement Data

Sign up for Robert Langdon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References